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Behavioral/Cognitive
Designer Receptors Enhance Memory in a Mouse Model of
Down Syndrome
Ashley M. Fortress,1* Eric D. Hamlett,1* Elena M. Vazey,1 Gary Aston-Jones,1Wayne A. Cass,3Heather A. Boger,1
and Ann-Charlotte E. Granholm1,2
1Department of Neurosciences and 2Center on Aging, Medical University of South Carolina, Charleston, South Carolina 29425, and 3Department of
Anatomy and Neurobiology, University of Kentucky College of Medicine, Lexington, Kentucky 40506
Designer receptors exclusively activated by designer drugs (DREADDs) are novel and powerful tools to investigate discrete neuronal
populations in the brain. We have used DREADDs to stimulate degenerating neurons in a Down syndrome (DS) model, Ts65Dn mice.
Individuals with DS develop Alzheimer’s disease (AD) neuropathology and have elevated risk for dementia starting in their 30s and 40s.
Individuals with DS often exhibit working memory deficits coupled with degeneration of the locus coeruleus (LC) norepinephrine (NE)
neurons. It is thought that LC degeneration precedes other AD-related neuronal loss, and LC noradrenergic integrity is important for
executive function, working memory, and attention. Previous studies have shown that LC-enhancing drugs can slow the progression of
AD pathology, including amyloid aggregation, oxidative stress, and inflammation.We have shown that LC degeneration in Ts65Dnmice
leads to exaggeratedmemory loss andneuronal degeneration.WeusedaDREADD,hM3Dq, administered via adeno-associated virus into
the LC under a synthetic promoter, PRSx8, to selectively stimulate LC neurons by exogenous administration of the inert DREADD ligand
clozapine-N-oxide.DREADDstimulationof LC-NEenhancedperformance in anovel object recognition task and reducedhyperactivity in
Ts65Dnmice,without significantbehavioral effects in controls. To confirm that thenoradrenergic transmitter systemwas responsible for
the enhancedmemory function, theNEprodrug L-threo-dihydroxyphenylserinewasadministered inTs65Dnandnormosomic littermate
control mice, and produced similar behavioral results. Thus, NE stimulation may prevent memory loss in Ts65Dn mice, and may hold
promise for treatment in individuals with DS and dementia.
Key words: designer receptors; Down syndrome; hippocampus; locus coeruleus; neurodegeneration; noradrenergic
Introduction
Down syndrome (DS) is themost prevalent intellectual disability
with an incidence of 1 in 800 live births with 250,000 people
affected in theUnited States (Zigman, 2013). Individuals withDS
exhibit high comorbidity with Alzheimer’s disease (AD; Nelson
et al., 2005; Krinsky-McHale et al., 2008; Glasson et al., 2014) and
AD neuropathology (Wisniewski et al., 1985). DS-related AD
(DS-AD) encompasses classic AD hallmarks includingmicroglial
activation, -amyloid plaques (Head et al., 2001), and neurofi-
brillary tangles (Stoltzner et al., 2000), which lead to progressive
neurodegeneration of basal forebrain cholinergic neurons, locus
ceruleus (LC) neurons, and hippocampal neurons (Granholm et
al., 2000; Hunter et al., 2004; Salehi et al., 2009; Lockrow et al.,
2011; Schliebs and Arendt, 2011). The average lifespan of indi-
viduals with DS has increased lately due to improved healthcare
(Zigman, 2013). There are currently no successful therapeutic
strategies to prevent DS-associated AD (Glasson et al., 2014; Iu-
lita et al., 2014). Therefore, the development of therapeutic or
preventive agents for comorbid symptoms of AD is paramount to
the highly susceptible DS population.
TheLCnucleus is themain sourceofnorepinephrine (NE) to the
hippocampus (Loy et al., 1980) and is a critical modulator of hip-
pocampal and frontal cortex synaptic plasticity (Stanton andSarvey,
1985; Bramham et al., 1997; Morris et al., 2003; Vazey and Aston-
Jones, 2012). The LC-neurons degenerates early in AD and in
DS-AD (Mann et al., 1986; German et al., 1992). LC-NE lesions,
using the selective NE neurotoxin DSP-4 [N-(2-chloroethyl)-N-
ethyl-2-bromobenzylamine], leads toaggravatedamyloidpathology
in AD mouse models (Kalinin et al., 2007), and we have demon-
strated that AD neuropathology and cognitive impairment are ag-
gravated by LC-NE lesions in a mouse model of DS, the Ts65Dn
mouse (Lockrowet al., 2011). Ts65Dnmicehave a triplicationof the
centromere andproximal endof chromosome17, and thedistal end
of mouse chromosome 16, syntenic to 60% of genes triplicated in
Human DS (Hsa21; Davisson et al., 1990). Ts65Dn mice exhibit
accelerated atrophy and degeneration of basal forebrain, hippocam-
pal, and LC-NE neurons, in addition to accelerated memory loss in
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several cognitivedomainsandhyperactivity (Escorihuela et al., 1995;
Lockrow et al., 2012; Ruparelia et al., 2013). Treatment with the NE
precursor L-threo-dihydroxyphenylserine (L-DOPS) enhanced con-
textual learning in Ts65Dn mice (Salehi et al., 2009). However, a
direct connection between LC signaling and hippocampal-
dependent behavior can provide additional information by using a
targeted approach such as the designer receptors used here.
Targeted expression of genetically modified designer recep-
tors exclusively activated by designer drugs (DREADDs) is an
innovative tool that can be used to enhance neuronal activity
(Vazey and Aston-Jones, 2014) and discrete neuronal popula-
tions (Clark et al., 2000; Nawaratne et al., 2008; Alexander et al.,
2009; Pei et al., 2010). We used DREADDs in LC-NE neurons
under control of the synthetic PRSx8 promoter for dopamine-
hydroxylase (DBH; Vazey and Aston-Jones, 2014) to limit distri-
bution of the DREADDs to LC-NE neurons. Stimulation of the
inserted DREADDs using clozapine-N-oxide (CNO) gave rise to
the normalization of memory behavior in Ts65Dn mice, there-
fore introducing a novel method for demonstrating the influence
of discrete neuronal populations on behavior.
Materials andMethods
Animals. Male Ts65Dn mice and normosomic (NS) littermate controls
were obtained from The Jackson Laboratory. All mice were 11–13
months of age before treatment. Ts65Dnmice are partially trisomic for a
segment of murine chromosomes 16 and 17, as described in detail by
Davisson et al. (1990), and have been used by our laboratory routinely
(Lockrow et al., 2009, 2010; for review, see Lockrow et al., 2012). All mice
were single housed, received food and water ad libitum, and were main-
tained on a 12 h light/dark cycle. All experimental procedures were ap-
proved by the Institutional Animal Care and Use Committee of the
Medical University of South Carolina in accordance with the guidelines
described in the National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
Intracranial microinjection of adeno-associated virus PRSx8 hM3Dq.
PRSx8-hM3Dq HA vector (2  1012 transduction units/l; Vazey and
Aston-Jones, 2014) was cloned and packaged with adeno-associated vi-
rus (AAV) 2/9 serotype at the University of Pennsylvania Vector Core.
The PRSx8 promoter (Hwang et al., 2001) was used to drive the expres-
sion of the hM3Dq designer receptor with a C-terminal HA1.1 tag for
identification (Armbruster et al., 2007; Alexander et al., 2009; provided
by Bryan Roth, University of North Carolina, Chapel Hill, NC). NS (n
7) and Ts65Dn (n  6) male mice were anesthetized with ketamine/
xylazine (120/6mg/kg, i.p.) and given a long-acting local anesthetic in the
skin overlying the injection site (bupivacaine, 1 mg/kg, s.c.) before sur-
gery. Anesthetized mice were placed in a rodent stereotaxic apparatus
with a mouse adaptor, and intracranial injections of AAV were delivered
bilaterally into the LC via a Hamilton syringe at the following stereotaxic
coordinates:5.34 anteroposterior,2.5 dorsoventral,1.0 mediolat-
eral from bregma (Paxinos and Franklin, 2004). AAV was delivered at a
rate of0.1l/min over 10min for a total volume of 1.0l per injection
site. After microinjection, the syringe was left in place for 10 min to limit
diffusion into the injection track. Animals were then sutured, removed
from the apparatus, and monitored for full recovery before returning to
disposable cages housed in a biological safety level 2 room. Behavioral
testing began 20 d after the AAV injections.
Spontaneous locomotor activity. All mice in the hM3Dq study were ob-
served for overall locomotor activity to monitor changes in motor activity
that may have resulted from AAV injection and/or CNO stimulation of the
DREADDs. Spontaneous activity was measured using the Digiscan Animal
Activity Monitor system, and horizontal and vertical activity were collected
asdescribedpreviously (Bogeretal., 2006;Lockrowetal., 2011).Briefly,mice
were placed in a darkened testing chamber and allowed to move freely
through photo beambreaks in the x-, y-, and z-axes for 1 hwith sampling at
5 min intervals. Data were analyzed using Digiscan software.
Novel object recognition task.We have previously used the novel object
recognition task (NORT) in Ts65Dn mice, showing a significant deficit
in discrimination of novel versus familiar objects, after both a short and
long delay interval (Lockrow et al., 2011). Briefly, mice were individually
placed in the testing arena (40 cm long 40 cm wide30 cm high) for
a period of 5 min with no objects present for habituation purposes. On
the next day of testing, mice were placed in the chamber with two iden-
tical objects placed in the northeast and northwest corners (2 inches
from the side of the chamber and 6 inches apart). Interactions with both
objects were recorded for 15 min with a digital video camera mounted
overhead. After a 90min delay, mice were placed in the chamber with the
following two objects: a familiar object from the preceding set; and a
novel object. Interactions with both objects were recorded for 15 min.
The spatial location for the objects remained the same throughout test-
ing. Videos were scored for both the frequency and duration of time with
each object by a blind observer. For each study, the following two depen-
dent measures were calculated: the percentage of time spent with the
novel object and the discrimination index (DI; Lockrow et al., 2009,
2011). The DI represents the net time spent with the novel object relative
to the total time spent with both objects. This task was the primary behav-
ioral outcome for the two studies, and was used for both the DREADD and
the L-DOPS studies to compare behavioral results between the two differ-
ent treatment paradigms (see Figs. 3, 4, respectively).
Spontaneous alternation task. The spontaneous alternation plus maze
is an index of hippocampus-dependent spatial workingmemory (Savage
et al., 2003), and mouse models of DS show deficits in this task (Kaur et
al., 2014). The four-arm spontaneous alternation task (SAT) is nonap-
petitive and nonaversive. Mice were placed in the center of the maze and
recorded by an unbiased observer while they were allowed to explore all
four equally spaced arms at random for a total of 12min. An entry into an
arm was recorded when all four paws entered an arm. After the comple-
tion of testing, the mouse was returned to its home cage. The percentage
of alternations was calculated as described by others (Stefani and Gold,
2001). Briefly, the number of alternationswas calculated by allowing only
one repeat entry in a series of five entries, which was analyzed in a series
of overlapping quintuplets. The percentage of alternation is the number
of alternationsmade relative to the total possible number of alternations,
expressed as a percentage. For example, 1 432 341 342 would be four of
six possible alternations (number of entries, four; 67%).
DREADD hM3Dq study design. Ts65Dn mice (n  6) and littermate
control NS mice (n  7) were tested 20 d after intracranial surgery to
allow receptor translation/trafficking. Mice received 0.3 mg/kg CNO
(Sigma) intraperitoneally in sterile water or sterile water alone [vehicle
(VEH)], 5 min before the start of behavioral testing, according to previ-
ously published protocols (Alexander et al., 2009; Vazey and Aston-
Jones, 2014). Mice received an injection with either CNO (0.3 mg/kg) or
VEH in a randomized crossover design. Following CNO dosing, mice
were placed in locomotor activity chambers for 1 h immediately before
habituation in the NORT arena. The following day, all mice were given
the respective injections again and were evaluated in the NORTmemory
task. After 2 d, to ensure CNO clearance, the treatments were switched
for each mouse followed by habituation and NORT memory testing.
Mice were killed, and the brains were rapidly extracted within 1 week of
behavioral testing (see Fig. 2A, schematic).
L-DOPS study design. Ts65Dnmice (L-DOPS, n 6; VEH, n 6) and
littermate control NS mice (L-DOPS, n  6; VEH, n  5), which were
male and 11 months of age, were injected with L-DOPS plus carbidopa
(L-DOPS) or with carbidopa alone (VEH) for 2 weeks every other day
(see Fig. 4A, experimental design). Carbidopa (Chelsea Therapeutics In-
ternational, Ltd.)wasmanufactured in a solution of 0.2MHCl containing
2 mg/ml ascorbic acid to prevent oxidation and was coadministered to
decrease peripheral sympathetic activation (see also Kato et al., 1987;
Salehi et al., 2009). The ascorbic acid was neutralized immediately before
injection with a 6.6l/ml 10 MNaOH solution to reach a pH of 7.0. Mice
received subcutaneous injections of either carbidopa at 0.125 mg/g body
weight at an injection volume of 0.02 ml/g or carbidopa plus L-DOPS
(200 mg/kg; Chelsea Therapeutics International, Ltd.). On test days, in-
jections were made 5 h before tests since the concentration of L-DOPS
peaks in rodents after 5 h in vivo (Kato et al., 1987). After 2 weeks of
L-DOPS treatment, all subjects were evaluated by NORT and an SAT
1344 • J. Neurosci., January 28, 2015 • 35(4):1343–1353 Fortress, Hamlett et al. • DREADD hM3Dq-Enhanced Memory in Down Syndrome
according to our previous protocols (Lockrow et al., 2011, 2012) and as
described in detail above.
Tissue preparation.Within 1 week of behavioral testing, all mice were
killed using an overdose of isoflurane, and the brains were rapidly dis-
sected. Tissues were divided for HPLC or immunohistochemistry ac-
cording to our standard procedures (Boger et al., 2011; Lockrow et al.,
2011). The right frontal cortex and right hippocampus were dissected for
catecholamine tissue levels, placed into preweighed tubes, weighed for
tissue weight, snap frozen on dry ice, and stored at80°C until use. The
remaining brain tissue was placed into 4%paraformaldehyde for 48 h for
immersion fixation, then placed into 30% sucrose in PBS for at least 72 h
before sectioning at 40 m on aMicrom cryostat (Thermo Fisher Scien-
tific) for immunohistochemistry.
Immunostaining.Thehippocampus and the pontine region containing
the LCwere sectioned at 40mandprocessed for immunohistochemical
analyses, as described previously (Lockrow et al., 2011). Briefly, series of
every sixth section were blocked in 10% NGS in TBS-Triton X-100 and
incubated with anti-1 receptor (1:500; Santa Cruz Biotechnology), or
anti-tyrosine hydroxylase (TH; 1:1000; Pel-Freeze) and anti-HA anti-
bodies (1:1000; Cell Signaling Technologies) overnight at room temper-
ature. The sections processed for fluorescence
microscopy (HA and TH immunohistochem-
istry) were then incubated for 1 h with second-
ary antibodies directed against the appropriate
species, conjugated with TRITC or FITC, re-
spectively (1:200; Jackson ImmunoResearch).
Sections stained for the 1 receptor or TH di-
aminobenzidine (DAB) staining (Fig. 1) were
incubated with biotinylated anti-rabbit sec-
ondary antibodies, then ABC solution (Vector
Laboratories) followed by development with
DAB (Sigma; see Lockrow et al., 2011). The
tissue was mounted onto slides, dehydrated,
and coverslipped with Permount (Fisher Sci-
entific). All images we captured using a Nikon
Eclipse E-600 microscope equipped with a
Qcam digital camera.
Densitometry and cell counting. To deter-
mine the staining density of1NE receptors in
the hippocampus, a series of every sixth section
throughout the rostrocaudal extent of the hip-
pocampus was evaluated. Images were ac-
quired on a Nikon microscope, with settings
remaining identical across all image acquisi-
tions. Using the NIS Elements Advanced Re-
search software system (Nikon Instruments),
the region of interest was outlined to include
the upper and lower blades of the dentate gyrus
and lateral border of the granule cell layers in
the dentate. TheNIS Elements software uses an
8-bit scaling system (0–256 gray levels). The
average staining density in the hippocampus
was averaged across all sections per animal
(9–12 sections). Background correction was
obtained by subtracting the mean of three un-
stained background measurements on each
section from the mean density measurement
(Hunter et al., 2003a,b). Confocal laser scan-
ning microscopy (Fluoview BX61, Olympus)
was used to generate 3D images of at least seven
randomly distributed sections from the locus
ceruleus in both normosomic and Ts65Dn
mice. NIS Elements softwarewas used to deter-
mine the percentage of HA-labeled TH-
positive LC neurons based on blind hand
counting. Specifically, all TH-positive neurons
in the LC (Fig. 2, green fluorescence) were
counted in multiple sections from each brain.
Thereafter, all TH-immunoreactive neurons
colabeled with HA (Fig. 2, red fluorescence)
were counted on the same sections, and the data were expressed as the
percentage of TH-positive neurons that also contained HA fluorescence
(Fig. 2H ).
HPLCanalysis. Samples were sonicated in 300l of cold 0.1 M perchlo-
ric acid containing dihydroxybenzylamine as an internal standard. They
were then centrifuged for 5 min at 12,000 g, and the supernatant was
filtered through a 0.22-m-pore size membrane (Ultrafree Centrifugal
Filter, Millipore). The filtrate was then assayed for NE using HPLC, as
previously described (Cass et al., 2003).Tissue levels ofNE for eachmouse in
the study were expressed in nanograms per gramwet weight of tissue.
Statistical considerations. One-factor ANOVA was used for compari-
son between the groups, eliminating the need for multiple pairwise hy-
pothesis tests. A t test was conducted between treated and untreated NS
groups (CNO or L-DOPS treated), and no statistical effects of the treat-
ments were observed in any of the outcome measures between the two
NS groups (see each figure legend), except in the NE receptors (see Fig.
5). The expected outcome from these studies was therefore directed spe-
cifically toward treatment effects in the two Ts65Dn groups, as well as
statistical differences between vehicle-treated NS and Ts65Dn groups.
Figure 1. TH immunostaining in the LC-NE region of Ts65Dnmice and NSmice at 4 and 12months of age. A, B, At 4months of
age, there was no difference in terms of TH staining density between NS (A) and Ts65Dn (B) mice. C, D, However, at 12months of
age, there was a marked reduction in TH-immunoreactive fiber density and cell-packing density in Ts65Dn mice (D), compared
with NS mice (C). TH-positive LC cell bodies had observable degenerative morphology, including a pyknotic nucleus and reduced
intracellular TH staining in Ts65Dn mice (D). Representative images taken at 10magnification. Scale bar, 200m.
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Following examination of the statistical rela-
tionship between treated and untreated NS
groups, the two NS groups were collapsed and
compared with the two Ts65Dn groups using
an ANOVA overall analysis. Tukey’s post hoc
analysis was used for all post hoc tests to exam-
ine statistical patterns that were not specified a
priori, and post hoc results were reported with
an acceptable  value of p  0.05. Pearson
product moment correlation (PPMC) was
used to determine relationships between be-
havioral and biochemical data (see Fig. 5). All
statistics were performed with GraphPad
Prism6 software (version 6.04), and all data are
presented as the mean SEM.
Results
LC degeneration in Ts65Dn mice
Immunohistochemical assessment of the
LC-NE region using TH antibodies re-
vealed a marked loss of both TH-positive
cell bodies and neurites in the LC region
in middle-aged Ts65Dn mice compared
with NS mice (Fig. 1). The loss of TH-
immunoreactive neurons in the LC was
not observed at earlier ages (4-month-old
Ts65Dn and NS mice; Fig. 1A,B). TH-
stained sections in 12-month-old Ts65Dn
mice revealed atrophic neurons as well as
swollen and dystrophic neurites in the LC
(Fig. 1D), and reduced TH stainingwithin
neuronal cell bodies. It is established that
the LC begins to degenerate as early as 6
months of age in Ts65Dn mice (Salehi et
al., 2009), with a significant loss of neurons
observed by our group at 12 months of age
using unbiased stereological cell counting
(Lockrow et al., 2011). The age ofmice cho-
sen for the current study was based on the
LC-NE cell loss observed at this age.
To determine the transduction effi-
ciency of the vector in LC-NE neurons of
the pons, we performed immunostaining
of the HA tag included in the viral con-
struct, using double labeling with TH and
HA antibodies (Fig. 2). Five weeks postin-
jection, robust expression of the HA tag
was observed in the LC region using
immunofluorescence in both NS (Fig.
2B–D) andTs65Dnmice (Fig. 2E–G). Co-
labeling of HA and TH revealed that an
average of 98% of TH-positive cells in the
LC also costained with the HA1.1-tagged
DREADD receptor (sampling was per-
formed in 19 sections in five subjects, in
bothNSandTs65Dnmice; rangeof colabel-
ing, 86–100%; see Fig. 2H). Anterograde
hM3Dq receptor trafficking in axons adja-
cent to the LC nucleus was observed, sug-
gesting a functional integration of the
DREADDs into LC neurons (Fig. 2I, white arrows). The HA-TH
double labeling demonstrated that AAV transduction of the DRE-
ADD receptors in LC-NEneuronswas successful, efficient, and spe-
cific to the LC neurons, in both NS and in Ts65Dnmice.
DREADD hM3Dq-mediated behavior
Stimulation of the hM3Dq receptor with the pharmacologically
inert agent CNO facilitates neuronal tonic increases in target
neurons (Armbruster et al., 2007; Vazey and Aston-Jones, 2014).
The same hM3Dq construct used in the current study has re-
Figure 2. THandHA immunostaining in theLC.A, Experimental design for theDREADDstudy. TheAAV-HA tagvectorwas injectedvia
stereotaxic injections into Ts65Dn or NSmice. Twenty days after surgery,micewere tested for behavior. After a 2 dwashout period,mice
weregiventheopposite treatment inacrossoverdesign.B–D, TH immunostaining(B, green),HAstaining(C, red), andoverlay (D, yellow)
inanormosomicmouseLC.E–G, TH (E, green),HA (F, red), andoverlay (G, yellow) in theLCofaTs65Dnmouse.H, Transductionefficiency
table, showing range, mean, and SD measured in a total of 19 double-labeled sections. I, FITC-labeled HA immunostaining
in the LC region at a higher magnification, with evidence of axonal transport of the DREADD receptors (arrowheads). Scale
bars: D, G, 100m; I, 40m.
1346 • J. Neurosci., January 28, 2015 • 35(4):1343–1353 Fortress, Hamlett et al. • DREADD hM3Dq-Enhanced Memory in Down Syndrome
cently been used by others in our group to demonstrate increased
firing rates of LC neurons (Vazey and Aston-Jones, 2014). Statis-
tical analysis of the two NS groups (with or without CNO injec-
tions) revealed that NSmice showed no significant differences in
locomotion (p 0.673), time spent in the center (p 0.847), or
object discrimination in the NORT task after hM3Dq activation
with CNO (p  0.522), as evident from the graphs in Figure
3A–C. Based on these findings, the two NS groups have been
collapsed for the purpose of examining a priori the effects of
trisomy and CNO plus trisomy compared with NS mice.
Because hyperactivity has been observed in theTs65Dnmouse
model and may influence other behavioral components, we first
examined the effects of LC hM3Dq stimulation on baseline mo-
tor activity in Ts65Dnmice (Fig. 3A). Both NS and Ts65Dnmice
without CNO exhibited spontaneous behavior similar to what we
have previously reported for age-matched mice of both karyo-
types (see Lockrow et al., 2011), strongly
indicating that theAAV injection itself did
not give rise to alterations in spontaneous
activity. An ANOVA analysis revealed
overall statistical differences between the
groups (F(2,15)  5.101; p  0.0249), and
post hoc analysis (Tukey’s test) further re-
vealed that vehicle-treated Ts65Dn mice
displayed significantly increased sponta-
neous activity relative to NS control mice
(p  0.0231), revealing hyperactivity in
Ts65Dn mice. CNO injections in Ts65Dn
mice significantly attenuated hyperactivity,
with CNO-treated Ts65Dn mice exhibiting
significantly less total activity than vehicle-
treated Ts65Dn mice (Tukey’s test, p 
0.0111). CNO-treated Ts65Dn mice were
not significantly different in overall activ-
ity than NS control mice (p  0.4508),
suggesting that stimulating hM3Dq re-
ceptors restored spontaneous activity to
levels observed in NSmice. Next, the time
spent in the center of the activity arena
was evaluated, and an overall ANOVA
also revealed significant group differences
for this measure (F(2,15)  5.315; p 
0.0243; Fig. 3B). Interestingly, although
vehicle-treated Ts65Dn mice were signif-
icantly more active than NS mice, they
spent significantly less time in the center
of the open field arena relative toNSmice,
as revealed using post hoc analysis (Fig. 3B;
p  0.0088). However, Ts65Dn mice
treated with CNO spent significantly
more time in the center of the open field
arena compared with nontreated Ts65Dn
mice (p 0.0291), with times spent in the
center that were comparable to those ob-
served in NS mice, suggesting that stimu-
lating LC hM3Dq receptors reduced
anxiety-like behavior and hyperactivity in
Ts65Dn mice. The spontaneous locomo-
tion data are the first to demonstrate
that hM3Dq/CNO stimulation of LC-NE
can acutely reduce hyperactivity in the
Ts65Dn mouse model, without exerting
any effects on either total activity or on
time spent in the center in NS mice transfected with the
DREADDs.
Novel object recognition task
We first evaluated whether or not hM3Dq-mediated stimulation
of the LC could alleviate memory deficits in Ts65Dn mice at an
age when LC degeneration and cognitive impairment are both
apparent (Lockrow et al., 2011; Fig. 1). Twenty days after AAV
injection, we tested NS and Ts65Dn in the novel object recogni-
tion task. All mice received an intraperitoneal injection of either
CNO or vehicle on each day of the task, 5 min before testing. To
determine whethermice had a preference for the novel object, we
first calculated the percentage of time spent with the novel object.
A Student’s t test between the two NS groups revealed that there
was no significant difference between CNO- or vehicle-treated
NSmice in terms of discrimination index in NORT (p 0.6470;
Figure 3. Behavioral outcomes of the DREADD experiment. A, Spontaneous locomotion. Vehicle-treated Ts65Dn (TS) mice
exhibited a significant increase in the total distance traveled (m), whichwas attenuatedwith CNO treatment.B, Time spent in the
center. Vehicle-treatedTs65Dnmice spent less time in the center of anopen-field comparedwithNSmice,whichwas reversedwith
CNO treatment. C, NORT. Vehicle-treated Ts65Dn mice spent significantly less time with the novel object than NS mice, and this
deficiency was normalized after treatment with CNO, with a significant difference between Ts65Dn mice with or without CNO. D,
Discrimination index for theNORT.NSmicewere significantlymore likely to recognize thenovel object thanvehicle-treatedTs65Dn
mice, which were normalized after CNO treatment. Error bars represent the mean SEM. There was no significant difference
between the NS VEH and CNO groups for any of these measures. *p 0.05; **p 0.01.
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Fig. 3D); therefore, the two NS groups
were collapsed for further comparison
with the Ts65Dn groups. An overall
ANOVA between NS mice versus the two
Ts65Dn groups revealed group differ-
ences for time spent on the novel object
between Ts65Dn mice with or without
CNO treatment and NS mice (F(2,21) 
4.623; p 0.0231). Tukey’s post hoc anal-
ysis revealed that the mean time spent
with the novel object was significantly less
in vehicle-treatedTs65Dnmice compared
withNSmice (Fig. 3C; p 0.048). Impor-
tantly, the AAV injection per se did not
appear to exert any behavioral effects,
since non-AAV-injected NS and Ts65Dn
control mice in the L-DOPS experiment
(Fig. 4B,C) exhibited close to identical
performance in both the time on novel
object (Fig. 4B) and discrimination index
(Fig. 4C) as the AAV-injected NS and
Ts65Dnmice with vehicle in the DREADD
experiment. The CNO injection reversed
the NORT deficits in Ts65Dn mice, as
CNO-treated Ts65Dn mice exhibited a
significant increase in the percentage of
time spent with the novel object com-
pared with vehicle-treated Ts65Dn mice
(p  0.029). Importantly, CNO-treated
Ts65Dn mice were able to discriminate
the novel object just as effectively as NS
mice (p  0.8675; Fig. 3D), suggesting
that hM3q LC stimulation restored cogni-
tion to levels observed in NS mice.
Because the percentage of time spent
with the novel object does not readily in-
dicate behavioral perseverance, we also
calculated the DI for each group of mice.
An overall ANOVA of DI values for each
group revealed overall statistical differ-
ences between the groups (F(2,21) 3.821;
p 0.0414). No statistical difference inDI
was observed between the vehicle- and
CNO-treated NS mice (p  0.6470).
Vehicle-treated Ts65Dn mice were signif-
icantly less likely to discriminate the novel
object from the familiar one, compared
with NS mice (p  0.0238), as indicated
by the negative DI value. The inability to
discriminate the familiar object observed
in vehicle-treated Ts65Dn mice was re-
versed by CNO, as CNO-treated Ts65Dn
mice significantly preferred the novel ob-
ject compared with the familiar object
during the discrimination phase (p 
0.0267). Collectively, these findings sug-
gest that hM3Dq/CNO-mediated LC activation can enhance cog-
nition inmiddle-aged Ts65Dnmice by reducing delayedworking
memory deficits and reducing behavioral perseverance. Age-
matched Ts65Dn and NS control mice without AAV injection
surgery included in the L-DOPS experiment (see below) exhib-
ited close to identical behavioral performance compared with
Ts65Dn and NS mice with injections of AAV plus vehicle,
strongly suggesting that the AAV injections did not give rise to
behavioral alterations without CNO-mediated DREADD stimu-
lation. Thus, the data in experiments 1 and 2 demonstrated that
AAV injections per se did not alter behavioral performance in the
NORT, either in NS or Ts65Dn mice.
These results show that hM3Dq-mediated enhancement of
LC-NE activity in residual LC neurons of middle-aged Ts65Dn
Figure 4. Behavioral outcomes of the L-DOPS experiment. A, Experimental design. Ts65Dn (TS) and NS mice received L-DOPS
injections every second day for 2 weeks before behavioral testing, and every day during the behavioral testing. B, NORT. Vehicle-
treated Ts65Dnmice spent significantly less timewith the novel object thanNSmice; however, L-DOPS-treated Ts65Dnmice spent
significantly more time with the novel object than vehicle-treated TS mice. C, Discrimination index. Vehicle-treated Ts65Dn mice
exhibited a significant decrease in their ability to detect a novel object compared with NSmice, but this impairment was reversed
with L-DOPS treatment.D, Spontaneous alternation task. Vehicle-treated Ts65Dnmicemade significantly fewer alternations than
NS mice; however, spatial working memory was restored in Ts65Dn mice after L-DOPS treatment, with a significant difference
detected between Ts65Dn mice with and without L-DOPS. As can be seen in the bar graphs, there was no significant difference
between the L-DOPS- and VEH-treated NS groups for any of these behavioral measures. inj., Injection. Error bars represent the
mean SEM. *p 0.05; **p 0.01.
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mice can exert significant beneficial effects on hyperactivity, cen-
ter activity, and performance in the NORT.
L-DOPS-mediated behavior
In the current study, a second experiment was undertaken using
pharmacological enhancement of NE neurotransmission with-
out the potential altering effects of AAV injections, to determine
whether the NE precursor L-DOPS could restore cognition in
Ts65Dn mice. NS and Ts65Dn mice were treated with either
vehicle or L-DOPS, which was administered three times per week
for 2weeks before behavioral testing and 5hbefore the start of the
behavioral task each day, similar to other previously published
articles (Ouyang and Thomas, 2005; Kalinin et al., 2007). We
wanted to first establishwhether L-DOPS could facilitatememory
for the familiar object in the novel object recognition task. An
overall ANOVA revealed significant group differences in an over-
all comparison (F(2,22) 3.976; p 0.0361).NSmice treatedwith
L-DOPS (n 5)were not statistically significant fromNS vehicle-
treated mice (n 6) in terms of either percentage of time spent
with the novel object (p 0.9526) or DI (p 0.1159), demon-
strating that this drug had no behavioral effects on NS mice (Fig.
4B,C). Compared with NS mice, a post hoc analysis revealed that
vehicle-treated Ts65Dnmice showed a significant impairment in
their ability to detect the novel object (p  0.0245; Fig. 4B).
However, the inability of vehicle-treated Ts65Dn mice to detect
the novel object was reversed by the NE prodrug L-DOPS, as
L-DOPS-treated Ts65Dnmice spent significantly more time with
the novel object than vehicle-treated Ts65Dn mice (p 0.0239;
Fig. 4B). However, there was no statistical significance between
L-DOPS-treated Ts65Dn and NS mice, suggesting that L-DOPS
corrected behavioral deficits in Ts65Dn mice (p  0.8013). An
overall ANOVA revealed significant group differences for DI as
well (Fig. 4C; F(2,22)  4.011; p  0.0343). In a post hoc analysis
(Tukey’s test), Ts65Dnmice exhibited a significant preference for
the familiar object as indicated by the negative DI value (p 
0.0235). However, upon treatment with L-DOPS, Ts65Dn mice
were able to detect the novel object, as L-DOPS-treated Ts65Dn
mice showed a significantly higher DI than vehicle-treated
Ts65Dn mice (p 0.0231), while L-DOPS-treated Ts65Dn mice
were not significantly different from the NS mice (p 0.6423).
Finally, it has been previously shown that the four-arm SAT is
ameasure of hippocampal function (Ragozzino et al., 1998), with
fewer alternations indicative of poor cognition (Savage et al.,
2003).When comparing overall alternation rates in this task in an
overall ANOVA, we also found significant group differences for
this task (F(2,22)  4.918; p  0.0167), and post hoc analysis re-
vealed that NS mice had a significantly higher percentage of al-
ternations than vehicle-treated Ts65Dn mice (p  0.0063),
suggesting that hippocampal function is reduced in 12-month-
old Ts65Dn mice compared with NS. However, no significant
differences were observed when the L-DOPS and VEH groups of
NSmicewere compared (p 0.4128). The alternation deficit was
reversed by L-DOPS, with Ts65Dn L-DOPS mice making signifi-
cantly more alternations than age-matched vehicle-treated
Ts65Dn mice (p  0.0187; Fig. 4D). There was no significant
difference between the NS vehicle-treated and Ts65Dn L-DOPS-
treated groups (p 0.8715), suggesting that the drug treatment
corrected spontaneous alternation deficits in Ts65Dnmice at this
age.Our behavioral results collectively suggest that administering
the systemic NE prodrug L-DOPS can improve hippocampal
function in Ts65Dn mice, in at least two different hippocampal-
dependent behavioral tasks, and therefore extend the findings of
previous studies regarding LC-enhancing drugs in DS mouse
models.
1 adrenergic receptor immunostaining
After 2 weeks of vehicle or L-DOPS treatment, 1 receptor im-
munostaining was examined in the hippocampus. Morphologi-
cal assessment of the receptor immunostaining revealed that
vehicle-treated NS and Ts65Dn mice had higher 1 receptor
staining density than the NS and Ts65Dn groups treated with
L-DOPS (Fig. 5C–F). Increased1 receptor immunostaining was
observed within neurons in the hilar region and in the granular
cell layer of the dentate. An overall ANOVA of 1 receptor stain-
ing density in the dentate revealed significant group differences
(F(2,21)  29.16; p  0.0001). Post hoc analysis (Tukey’s test)
demonstrated that vehicle-treated NS mice exhibited signifi-
cantly higher density of 1 receptor staining in the dentate com-
pared with L-DOPS-treated NS mice (p  0.0001; Fig. 5A).
Furthermore, vehicle-treated Ts65Dn mice had a significantly
higher 1 receptor staining density compared with L-DOPS-
treated Ts65Dn mice (p 0.0001). Importantly, vehicle-treated
Ts65Dnmice displayed a significantly higher1 receptor staining
density than vehicle-treatedNSmice (p 0.0015), whichmay, at
least partially, explain the behavioral deficits observed in vehicle-
treated Ts65Dnmice compared with age-matched NSmice. Col-
lectively, these data demonstrate that the NE prodrug L-DOPS
gives rise to a reduction in the expression of 1 receptors in the
hippocampus of both groups.
Finally, a PPMC correlation analysis revealed a significant
correlation between hippocampal NE levels, measured using
HPLC, and1 receptor staining density (Fig. 5B; p 0.019,R2
0.44). Therewere no groupdifferences in terms ofNE levels in the
hippocampus due to high variability within the groups, even
though a trend toward reduced NE levels was observed in the
Ts65Dn saline-treated group (data not shown). We did not ob-
serve significant correlations between1 receptor density and the
levels of other catecholamines in response to L-DOPS treatment
(data not shown).
Discussion
Our findings are the first to demonstrate that hM3Dq/CNO-
mediated LC activation restores memory function in middle-
aged Ts65Dn mice. Artificially stimulating LC-NE function
acutely via selective hM3Dq/CNO-mediated LC activation and
systemically via the NE prodrug L-DOPS enhanced cognition in
Ts65Dn mice in hippocampal-dependent behavioral tasks, in-
cluding the NORT and the SAT. When comparing behavioral
performance in the two experiments by group-to-group compar-
ison (Figs. 3, 4), the AAV injections themselves did not produce
any behavioral alterations in either Ts65Dn or NS mice. Ts65Dn
mice undergo a progressive loss of LC-NE neurons, beginning at
6months of age (Salehi et al., 2009; Lockrow et al., 2011), and the
current work extended and confirmed these findings. Stimula-
tion of the DREADD receptors with CNO also reduced hyperac-
tivity in Ts65Dn mice, and increased time spent in the center in
the spontaneous locomotion box, suggesting that hyperactivity
and anxiety may have been corrected with the LC-enhancing
DREADD activation. Further, double labeling using HA and TH
antibodies confirmed efficient and selective transduction of
DREADD receptors into LC-NEneurons, with an average of 98%
coexpression of TH and the HA tag. Immunostaining of 1 re-
ceptors confirmed an upregulation of noradrenergic receptor
staining in Ts65Dn mice, which was corrected by long-term
L-DOPS administration.
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Several pharmacological and genetic
manipulations in rodents have linked NE
production in the LC to hippocampal
function. Mice deficient in dopamine--
hydroxylase (DH knock-out mice) ex-
hibit memory retention deficits that can
be reversed by treatment with the 1 ago-
nist xamoterol (Murchison et al., 2004).
In humans with DS, the LC undergoes an
accelerated and significant degeneration
by as much as 60% compared with age-
matched non-DS brains (German et al.,
1992). The LC–hippocampal NE circuit is
important for blood–brain barrier
integrity, regulating neuroinflammatory
processes, and has direct effects on
learning and memory (for review, see
O’Donnell et al., 2012). It has been shown
that the development of AD pathology is
aggravated by LC-NE neurodegeneration
(Chalermpalanupap et al., 2013), and we
have reported similar findings regarding
DS-AD neuropathology in the Ts65Dn
mouse (Lockrow et al., 2011). In a recent
study, Hammerschmidt et al. (2013)
crossed DH knock-out mice with amy-
loid precursor protein (APP)/presenilin-1
(PS1) mice overexpressing mutant APP
and PS1. They found that LC-NE loss in
the AD mouse leads to greater deficits in
hippocampal-dependent memory tasks,
and that L-DOPS administration allevi-
ated these effects, providing additional ev-
idence for the important role of LC-NE
neurons in neuropathology and memory
deficits occurring both in idiopathic AD
and in DS-AD. The current data extend
the knowledge in this area by demonstrat-
ing that stimulation of remaining LC-NE
neurons exerts powerful effects on behav-
ior related to hippocampal function.
The findings presented here are the
first to demonstrate that hM3Dq/CNO-
mediated LC activation can regulate cog-
nition in the Ts65Dnmouse model of DS.
Previously, our laboratory has shown that
the loss of LC-NE can exacerbate cogni-
tive impairment and neuropathology in
Ts65Dn mice (Lockrow et al., 2011), sug-
gesting a role for NE dysfunction in the
accelerated neuropathology observed in
Ts65Dn mice. We observed that artificially
restoring LC-NE function via selective
hM3Dq/CNO-mediated LC activation
and via the NE prodrug L-DOPS en-
hanced hippocampal-dependent memory in Ts65Dn mice, both
of which corroborate the findings of others demonstrating a role
for NE in facilitating cognition (Salehi et al., 2006, 2009; Dang et
al., 2014). Our group has recently shown that stimulation of
hM3Dq DREADD receptors in the LC-NE neurons by systemic
injection of the inert DREADD ligand CNO doubles the firing
frequency of LC-NE neurons and facilitates cortical EEG changes
(Vazey and Aston-Jones, 2014), suggesting that activation of
hM3Dq receptors following CNO administration can drive LC
neuronal firing rates. Vazey and Aston-Jones (2014) also found a
close to 100% transduction efficiency by the same construct in LC
neurons, corroborating the transduction efficiency observed in
this study (Fig. 2H). Our results presented herein expand upon
these studies by demonstrating that LC-NE activity driven by
CNO-mediated hM3Dq stimulation affects both consolidation
and retrieval of hippocampal-dependent memory in the Ts65Dn
Figure 5. 1 receptor immunostaining. A, Densitometry demonstrated overall differences in1 immunostaining among all
four groups, and post hoc analysis showed that L-DOPS treatment gave rise to a significant reduction in staining density in both NS
andTs65Dn (TS) groups to comparable levels. Error bars represent themean SEM.B, Correlation analysis of1 receptor staining
and NE levels in the hippocampus revealed a significant correlation (F 13.51, p 0.0019, R 2 0.44). NE concentration is
represented as nanograms per gram for the amount of NE/wet weight of tissue in grams. Dotted lines represent the 90% confi-
dence interval of the best fit line (n 20–25 per plot). C–F,1 immunostaining in the dentate/hilar region of the hippocampus.
Increased immunostainingwasobservedwithneuronsof thehilar region, aswell as in thedentategranule layer in theTs65Dnmice
versus age-matched NS controls. Scale bar, 200m. L-DOPS treatment for 2 weeks reduced adrenergic receptor staining differ-
ences between the groups. **p 0.01; ***p 0.001.
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DS mouse model. The findings also demonstrate that AAV-
DREADD intracranial injections resulted in a nearly complete
transduction of TH-positive LC neurons, suggesting that the
PRSx8–hM3Dq–HA vector represents an effective method for
assessing behavioral consequences of selectively stimulating or
inhibiting LC neurons using the newly developed DREADD
systems.
It has been shown that hippocampal NE plays an important
role in the retrieval of contextual information in memory pro-
cessing. Mice deficient in DH exhibit spatial and contextual
retrieval deficits (Thomas and Palmiter, 1997). Furthermore,
hippocampal infusions of the  receptor agonist isoproterenol
facilitates contextual fear memory in DH-deficient mice, sug-
gesting that activation of  receptors in the hippocampus are
necessary and sufficient for memory retrieval (Murchison et al.,
2004), and may be one mechanism by which LC-NE stimulation
via DREADD receptors enhanced memory in Ts65Dn mice.
Short-term DREADD-CNO stimulation in this study is unlikely
to elicit changes in immunostaining of 1 receptors, contrary to
the long-term administration of L-DOPS in the second, pharma-
cological, experiment (Fig. 5). The inability of Ts65Dn mice to
retrieve information is supported by previous studies demon-
strating that NE is necessary for hippocampal-dependent mem-
ory retrieval (Murchison et al., 2004; Zhang et al., 2013). The
DREADD/CNO experiment further demonstrates that acute ac-
tivation of a residual, albeit degenerating, LC–NE pathway,
is sufficient to normalize deficits in hippocampal-dependent
memory in Ts65Dn mice. This is supported by evidence that
pharmacologically restoring NE levels in Ts65Dn mice and in
Dbh-deficient mice enhances hippocampal-dependent memory
(Salehi et al., 2009; Dang et al., 2014; Murchison et al., 2011). In
addition to enhanced performance in the NORT, the LC-NE
stimulation in Ts65Dn mice via CNO gave rise to increased time
spent in the center and reduced hyperactivity in the spontaneous
locomotion chamber. Reduced time spent in the center may be a
reflection of anxiety as well as hyperactivity, which may lead to
reduced attention and/or performance inmemory tasks (Warner
et al., 2014). Specifically, impaired executive function is closely
connected to LC-NE degeneration (Vazey and Aston-Jones,
2012), and individuals with DS exhibit deficits in this cognitive
domain (Kittler et al., 2008; Lanfranchi et al., 2010). Therefore,
using NE-enhancing drugs for individuals with DS-ADmay lead
to significant improvement not only in memory, but also in
anxiety- and attention-related behaviors. This is especially im-
portant since classic AD medications may be less effective in the
treatment of DS-AD compared with idiopathic AD (Iulita et al.,
2014), and there are currently no effective medications available
to mediate cognition in DS patients.
As a second approach to demonstrate the importance of the
LC-NE system in regulating hippocampal function in Ts65Dn
mice, we used a systemic method that is more comparable to
options available in the clinic. L-DOPS, currently pending Food
andDrug Administration approval in the United States, is widely
prescribed in Europe and Asia for neurogenic orthostatic hypoten-
sion to treat symptoms associated with Parkinson’s disease and to
reduce side effects from hemodialysis (Isaacson and Skettini,
2014). We reasoned that L-DOPS would enhance hippocampal
function similar to measures observed with hM3Dq/CNO-
mediated LC activation in the first study, and long-term dosing
may reduce pathological1 noradrenergic receptor expression in
the hippocampus. Similar to acute regulation of the LC following
hM3Dq/CNO-mediated LC activation, long-term systemic
L-DOPS treatment also enhanced cognition in the NORT in
Ts65Dn mice. Specifically, Ts65Dn mice treated with L-DOPS
showed a reversal in cognitive deficits in both the NORT and the
spontaneous alternation task, suggesting that enhancing LC-NE
signaling can facilitate hippocampal function in middle-aged
Ts65Dnmice. Furthermore, L-DOPS treatment reduced 1 NER
expression. As expected following the LC-NE degeneration in the
target region, Ts65Dn mice show an increase in 1 NER in the
hilar region of the hippocampus due to a progressive loss of
LC-NE innervation (Salehi et al., 2009). Since1 receptor knock-
out mice exhibit impaired memory retrieval, an optimal expres-
sion level of these receptors may be necessary for performance in
hippocampal-dependent behavioral tasks (Murchison et al.,
2011), perhaps by regulating slow afterhyperpolarization to facil-
itate excitatory transmission, as suggested by others (Zhang et al.,
2013). Understanding the cellular mechanisms downstream of
1 receptor activation is necessary for facilitating hippocampal
memory in aging Ts65Dn mice may enhance the discovery of
novel drug targets for both the AD and DS-AD populations.
Collectively, our results suggest that artificially stimulating
LC-NE function in the short term via hM3Dq/CNO-mediated
LC activation and in the long term via the NE prodrug L-DOPS
enhanced cognition in middle-aged Ts65Dn mice. Our findings
expand previous findings by us and others (Murchison et al.,
2004, 2011; Salehi et al., 2009; Lockrow et al., 2011) suggesting
that the LC-NE pathway is a plausible target for new therapeutic
agents in treating DS-AD and idiopathic AD. This would repre-
sent an important therapeutic avenue, since DS-related dementia
currently has no effective treatment (Nelson et al., 2005) and
occurs with high incidence in the adult DS population. Utilizing
DREADD technology enables the discrimination of neuronal
contributions to complex behavior without actions on neighbor-
ing cells or peripheral systems. Our study provides direct evi-
dence for the feasibility of DREADD receptor technology to
explore the role of discrete neuronal populations in neurodegen-
erative disorders and to identify potential therapeutic agents.
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